Is the US AIDS Drug Assistance Program Cost-effective?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Each year, the US AIDS drug assistance program (ADAP) provides access to prescription drugs—including antiretrovirals—to more than 110,000 persons living with HIV (PLWH) who lack adequate medical insurance. PLWH on effective antiretroviral therapy live longer lives, with enhanced quality of life, and are less likely to transmit HIV to others. There are thus significant benefits associated with the ADAP program. But there also are substantial costs. A mathematical model was used to assess the cost-effectiveness of the US ADAP program. Findings indicate that by providing antiretrovirals to underinsured persons, the ADAP program prevented 3,191 secondary infections and saved 24,922 quality-adjusted life years in 2008. The net cost per quality-adjusted life year saved was $11,955, which suggests that the ADAP program is cost-effective by conventional standards.
- Kates J, Penner MC, Crutsinger-Perry B, Leggoe AW, Singleton N. National ADAP monitoring project: annual report. The Henry J. Kaiser Family Foundation (KFF) and The National Alliance of State and Territorial AIDS Directors (NASTAD) (2005).
- Carbaugh AL, Kates J, Crutsinger-Perry B, Ginsburg B, Penner MC. National ADAP monitoring project: annual report. The Henry J. Kaiser Family Foundation (KFF) and The National Alliance of State and Territorial AIDS Directors (NASTAD) (2009).
- Kaiser Family Foundation. AIDS drug assistance programs (ADAPs). 2009 Fact Sheet #1584. Accessed 2 July 2011 http://www.kff.org/hivaids/upload/1584_10.pdf.
- Johri, M, Paltiel, D, Goldie, SJ, Freedberg, KA (2002) State AIDS drug assistance programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care 40: pp. 429-441 CrossRef
- Chen, LF, Hoy, J, Lewin, SR (2007) Ten years of highly active antiretroviral therapy for HIV infection Med J Aust 186: pp. 146-151
- CD4+ count-guided interruption of antiretroviral treatment. NEJM 355: pp. 2283-2296 CrossRef
- Burman, WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW, for the SMART Study Group. The impact of episodic CD4 cell count–guided antiretroviral therapy on quality of life. J Acquir Immune Defic Synd 2008;47:185–193.
- Attia, S, Egger, M, Muller, M, Zwahlen, M, Low, N (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: pp. 1397-1404 CrossRef
- Cock, KM, Crowley, SP, Lo, Y-R, Granich, RM, Williams, BG (2009) Preventing HIV transmission with antiretrovirals. Bull World Health Organ 87: pp. 488-489 CrossRef
- Pinkerton, SD (2011) HIV transmission rate modeling: a primer, review, and extension. AIDS Behav 16: pp. 791-796 CrossRef
- Schackman, BR, Gebo, KA, Walensky, RP, Losina, F, Muccio, T (2006) The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 44: pp. 990-997 CrossRef
- Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making 2012; 32(3):459–69. http://mdm.sagepub.com/content/early/2012/01/03/0272989X11431609.full.pdf.
- Tengs, TO, Lin, TH (2002) A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 22: pp. 475-481 CrossRef
- Mannheimer, SB, Matts, J, Telzak, E, Chesney, M, Child, C, Wu, AW (2005) Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 17: pp. 10-22 CrossRef
- Vital signs: HIV prevention through care and treatment, United States. MMWR 60: pp. 1618-1623
- Cohen, MS, Chen, YQ, McCauley, M, Gamble, T, Hosseinipour, MC, Kumarasamy, N (2011) Prevention of HIV-1 infection with early antiretroviral therapy. NEJM 365: pp. 493-505 CrossRef
- Marks, G, Crepaz, N, Janssen, RS (2006) Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 20: pp. 1447-1450 CrossRef
- Quinn, TC, Wawer, MJ, Sewankambo, N, Serwadda, D, Li, C, Wabwire-Mangen, F (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. NEJM 342: pp. 921-929 CrossRef
- Laufer, FN (2005) Thresholds in cost-effectiveness analysis—more of the story. Value in Health 8: pp. 86-87 CrossRef
- Laupacis, A, Feeny, D, Detsky, AS, Tugwell, PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146: pp. 473-481
- Schrappe M, Lauterbach K. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries. AIDS 1998;12 (suppl A):S231–S238.
- Tengs, TO, Adams, ME, Pliskin, JS, Safran, DG, Siegel, JE, Weinstein, MC (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15: pp. 369-390 CrossRef
- Prejean, J, Song, R, Hermandez, A, Ziebell, R, Green, T, Walker, F (2011) Estimated HIV incidence in the United States, 2006–2009. PLoS ONE 6: pp. e17502 CrossRef
- Kaiser Family Foundation. AIDS drug assistance programs (ADAPs) with waiting lists or other cost-containment strategies, as of May 2011. Accessed 15 June 2011http://www.statehealthfacts.org/comparemaptable.jsp?ind=552&cat:11&sub=204&yr=1&typ=5.
- HIV surveillance—United States, 1981–2008. MMWR 60: pp. 689-693
- Pinkerton, SD (2007) How many sexually-acquired HIV infections in the US are due to acute-phase HIV transmission?. AIDS 21: pp. 1625-1629 CrossRef
- Is the US AIDS Drug Assistance Program Cost-effective?
AIDS and Behavior
Volume 17, Issue 1 , pp 1-4
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- AIDS drug assistance program
- Antiretroviral therapy
- Industry Sectors